Capsule Summary Slidesets

Share

Program Content

Activities

  • Chemo-IO vs IO for Low PD-L1
    FDA Pooled Analysis: Survival Outcomes With First-line Chemo-IO vs IO Alone for Treatment of Advanced NSCLC With PD-L1 Expression 1% to 49%
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2021

    Expires: June 04, 2022

  • KEYNOTE-799
    KEYNOTE-799: Phase II Trial of Pembrolizumab + Concurrent CRT in Unresectable Stage IIIA-C NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2021

    Expires: June 04, 2022

  • PACIFIC 5-Yr Update
    PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2021

  • CodeBreaK100 Update
    Phase II CodeBreaK100: Overall Survival and Exploratory Subgroup Analyses of Sotorasib in Pretreated KRAS p.G12C–Mutated NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2021

    Expires: June 06, 2022

  • TROPION-PanTumor01
    TROPION-PanTumor01: Phase I Dose Analysis of Datopotamab Deruxtecan, a Novel TROP2-Targeted ADC, in Pretreated Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • HER3-DXd in <i>EGFR</i>+ NSCLC
    Phase I Study of Patritumab Deruxtecan in Patients With EGFR-Mutated NSCLC and Resistance to EGFR TKI Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • BOS127238 in <i>RET</i>-altered Cancer
    Novel RET Inhibitor BOS172738 in RET-Altered Cancers Including RET Fusion–Positive NSCLC and RET Mutation–Positive Medullary Thyroid Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2021

    Expires: June 07, 2022

  • CHRYSALIS Update
    CHRYSALIS Phase I Trial: Amivantamab + Lazertinib in Osimertinib-Relapsed, Chemotherapy-Naive EGFR-Mutated Advanced NSCLC, Including Analyses of Biomarkers of Response
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • IMpower010
    IMpower010: Phase III Trial of Adjuvant Atezolizumab vs BSC in Resected Stage IB-IIIA NSCLC After Adjuvant Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2021

    Expires: June 08, 2022

  • CheckMate 227 Part 1: 4-Yr Update
    CheckMate 227 Part 1: 4-Yr Update of First-line Nivolumab + Ipilimumab vs Platinum-Doublet Chemotherapy in Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • CheckMate 9LA: 2-Yr Update
    CheckMate 9LA: 2-Yr Update of First-line Nivolumab + Ipilimumab With 2 Cycles of Chemotherapy vs Chemotherapy Alone in Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • Racial Disparities in NSCLC
    Biomarker Testing and Clinical Trial Enrollment in NSCLC: Retrospective Analysis of Racial Disparities
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 15, 2021

    Expires: June 14, 2022

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme